Skip to main navigation

Menu

Overview
News Releases
Events & Presentations
Scientific Publications
Governance
Financials
- SEC Filings
Stock
- Stock Quote & Chart
- Analyst Coverage
IR Resources

Scientific Publications

Show all

October 8, 2024

29th Annual Congress of the World Muscle Society

CONNECT1-EDO51: A 12-Week Open-Label Phase 2 Study to Evaluate PGN-EDO51 Safety and Efficacy in People with Duchenne Amenable to Exon 51 Skipping (Oral Presentation) 729.4 KB
CONNECT1 - EDO51: A 12-week open-label Phase 2 study to evaluate PGN-EDO51 safety and efficacy in people with Duchenne amenable to exon 51 skipping 727.5 KB
CONNECT2-EDO51: A Phase 2 placebo-controlled study to evaluate PGNEDO51 safety and efficacy in people with Duchenne amenable to exon 51 skipping 728.4 KB
Evaluation of PGN-EDODM1: FREEDOM-DM1 and FREEDOM2-DM1 Clinical Trials in Myotonic Dystrophy Type 1 826.7 KB
Single- and Repeat-Dose Nonclinical Data for PGN-EDO51 Demonstrated Favorable Pharmacology and Safety Profiles for the Treatment of DMD 922.7 KB
Nonclinical Data for PGN-EDODM1 Demonstrated Nuclear Delivery, Mechanistic and Meaningful Activity for the Potential Treatment of DM1 1 MB

October 6, 2024

20th Annual Meeting of the Oligonucleotide Therapeutics Society

Single- and Repeat-Dose Nonclinical Data for PGN-EDO51 Demonstrated Favorable Pharmacology and Safety Profiles for the Treatment of DMD 933.4 KB
Nonclinical Data for PGN-EDODM1 Demonstrated Nuclear Delivery, Mechanistic and Meaningful Activity for the Potential Treatment of DM1 1 MB
Nonclinical in vitro and in vivo data demonstrated low immunogenicity risk and favorable of PGN-EDO51 for the treatment of DMD 9.3 MB
Mechanistic characterization of enhanced delivery oligonucleotide (EDO) platform 7.2 MB

September 25, 2024

Oxford-Harrington Rare Disease Centre Symposium 2024

Advancing the Use of Peptide-Conjugated Oligonucleotides to Target Neuromuscular Disorders: Enhanced Delivery Oligonucleotides for DMD and DM1 1.4 MB

September 22, 2024

2024 Neuromuscular Study Group Annual Scientific Meeting

CONNECT2-EDO51: A Phase 2 placebo-controlled study to evaluate PGNEDO51 safety and efficacy in people with Duchenne amenable to exon 51 skipping 728.4 KB
CONNECT1 - EDO51: A 12-week open-label Phase 2 study to evaluate PGN-EDO51 safety and efficacy in people with Duchenne amenable to exon 51 skipping 727.5 KB
Evaluation of PGN-EDODM1: FREEDOM-DM1 and FREEDOM2-DM1 Clinical Trials in Myotonic Dystrophy Type 1 826.7 KB

September 4, 2024

RNA Leaders USA Congress

Advancing the Use of Peptide-Conjugated Oligonucleotides to Target Neuromuscular Disorders: Enhanced Delivery Oligonucleotides for DMD and DM1 2.1 MB

April 9, 2024

14th International Myotonic Dystrophy Consortium

FREEDOM-DM1: Phase 1 Study Design to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PGN-EDODM1 for Myotonic Dystrophy Type 1 1.6 MB

March 3, 2024

2024 MDA Clinical & Scientific Conference

CONNECT1-EDO51 and CONNECT2-EDO51: Phase 2 Study Designs to Evaluate Safety and Efficacy for Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping 858.3 KB
FREEDOM-DM1: Phase 1 Study Design to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PGN-EDODM1 for Myotonic Dystrophy Type 1 794.5 KB
PGN-EDO51: Single- and Repeat-Dose Nonclinical Data Demonstrated Potential for the Treatment of Duchenne Muscular Dystrophy (DMD) 2.4 MB
PGN-EDODM1: Single- and Repeat-Dose Nonclinical Data Indicated Mechanistic and Meaningful Activity for Potential Treatment of Myotonic Dystrophy Type 1 (DM1) 2.3 MB

November 6, 2023

19th Annual Meeting of the Oligonucleotide Therapeutics Society

FREEDOM-DM1: Nonclinical Data Support the Phase 1 Study Design to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PGN-EDODM1 in Adults with Myotonic Dystrophy Type 1 (DM1) 794.5 KB
Nonclinical Data Demonstrate the Potential of the Enhanced Delivery Oligonucleotide (EDO) PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy 3.3 MB
PGN-EDODM1 Nonclinical Data Demonstrated Mechanistic and Meaningful Activity for the Potential Treatment of Myotonic Dystrophy Type 1 (DM1) 6.3 MB

October 3, 2023

28th Annual Congress of the World Muscle Society

Three Novel Enhanced Delivery Oligonucleotide (EDO) Candidates for Duchenne Muscular Dystrophy Mediated High Levels of Exon 53, 45, and 44 Skipping 3 MB

September 6, 2023

Myotonia Dystrophy Foundation Conference

PGN-EDODM1 Nonclinical Data Demonstrate Mechanistic and Meaningful Activity for Potential Treatment of Myotonic Dystrophy Type 1 6.3 MB

March 22, 2023

Muscular Dystrophy Association Clinical and Scientific Conference

Nonclinical Data Demonstrate the Potential of the Enhanced Delivery Oligonucleotide (EDO) PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy 3.3 MB

Stock Information
Information Request
Financial Information
FAQ

Print Page
Email Alerts
RSS Feeds
Contact IR

Request Email Alerts

©

2024 PepGen Inc All Rights Reserved.

Privacy Policy
Cookie Policy
Accessibility